CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/EP2015/055848, filed Mar 19, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,988,541 | CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | ||
| US 11,919,961 | CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | ||
| US 9,944,709 | CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.